يعرض 1 - 16 نتائج من 16 نتيجة بحث عن '"network metanalysis"', وقت الاستعلام: 0.46s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    وصف الملف: application/pdf

    Relation: Open Research Europe; Vol. 1 (2022), p. 113; https://ddd.uab.cat/record/290541; urn:10.12688/openreseurope.14044.2; urn:oai:ddd.uab.cat:290541; urn:scopus_id:85141989174; urn:articleid:27325121v1p113; urn:pmid:37645196; urn:pmc-uid:10446035; urn:pmcid:PMC10446035; urn:oai:pubmedcentral.nih.gov:10446035; urn:oai:egreta.uab.cat:publications/e4f32806-49a7-4d90-8b16-4cfc5a05f69e

  4. 4
    Academic Journal
  5. 5
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12

    المساهمون: Trillos, Carlos Enrique, Manrique Hernández, Rubén Darío, Mantilla Gomez, Juan Carlos

    المصدر: Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. The Lancet. febrero de 2017;389(10068):519–27.
    Cook G, Clark RE, Morris TCM, Robertson M, Lucie NP, Anderson S, et al. A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma. Br J Haematol. septiembre de 2004;126(6):792–8.
    Sonneveld P, Schmidt-Wolf IGH, van der Holt B, el Jarari L, Bertsch U, Salwender H, et al. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial. J Clin Oncol. el 20 de agosto de 2012;30(24):2946–55.
    Harousseau J-L, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, et al. Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial. J Clin Oncol. el 20 de octubre de 2010;28(30):4621–9.
    Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. el 24 de noviembre de 2011;118(22):5752–8.
    Miguel JFS, Khuageva NK, Shpilberg O, Petrucci MT, Dmoszynska A, Schots R, et al. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med. 2008;12.
    Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. The Lancet. diciembre de 2010;376(9758):2075–85.
    Chen R, Tu Y, Cao Y, Liu L, Liang Y. Bortezomib-Dexamethasone or Vincristine-Doxorubicin-Dexamethasone as Induction Therapy Followed by Thalidomide as Maintenance Therapy in Untreated Multiple Myeloma Patients. J Int Med Res. octubre de 2011;39(5):1975–84.
    Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. The Lancet. julio de 2019;394(10192):29–38.
    Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. el 1 de marzo de 2012;97(3):442–50.
    Rajkumar SV, Rosiñol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, et al. Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. J Clin Oncol. el 1 de mayo de 2008;26(13):2171–7.
    Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. agosto de 2015;29(8):1721–9.
    Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, et al. Randomized Phase II Study of Bortezomib, Thalidomide, and Dexamethasone With or Without Cyclophosphamide As Induction Therapy in Previously Untreated Multiple Myeloma. J Clin Oncol. el 10 de enero de 2013;31(2):247–55.
    Zervas K, Mihou D, Katodritou E, Pouli A, Mitsouli CH, Anagnostopoulos A, et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann Oncol. agosto de 2007;18(8):1369–75.
    Rosiñol L., Rosiñol L., Oriol A., Teruel A.I., Hernández D., Blanchard M.J., et al. Pretransplant induction with VTD (bortezomib/thalidomide/dexamethasone) significantly improves PFS: Long-term results of the randomized phase 3 PETHEMA/GEM study. Clin Lymphoma Myeloma Leuk. 2015;15((Rosiñol L.; Rosiñol L.; Cibeira M.T.; Bladé J.) Hospital Clínic, IDIBAPS, Barcelona, Spain):e49–50.
    Repositorio EdocUR-U. Rosario
    Universidad del Rosario
    instacron:Universidad del Rosario

    وصف الملف: application/pdf

  13. 13
  14. 14
    Dissertation/ Thesis

    المؤلفون: Ellen Carrara Fonseca

    Thesis Advisors: Eduardo Melani Rocha, José Augusto Alves Ottaiano, Jayter Silva de Paula, Sidney Julio de Faria e Sousa

    المصدر: Biblioteca Digital de Teses e Dissertações da USPUniversidade de São PauloUSP.

  15. 15
  16. 16
    Dissertation/ Thesis